
Fulltext:
177860.pdf
Embargo:
until further notice
Size:
625.8Kb
Format:
PDF
Description:
publisher's version
Publication year
2017Source
FEBS Journal, 284, 16, (2017), pp. 2579-2591ISSN
Publication type
Article / Letter to editor

Display more detailsDisplay less details
Organization
Pharmacology-Toxicology
Journal title
FEBS Journal
Volume
vol. 284
Issue
iss. 16
Page start
p. 2579
Page end
p. 2591
Subject
Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life SciencesAbstract
Artemisinin-based combination therapy (ACT) has been adopted as a strategy to mitigate multidrug resistance to antimalarial monotherapies. ACT combines the rapid and effective but rather short plasma half-life antimalarial action of an artemisinin derivative with a longer acting partner drug. Although the exact mechanisms of action of artemisinins are not well understood, several studies have proposed multiple cellular targets of artemisinins with involvement of reactive oxygen species (ROS). Most of the currently used ACT partner drugs are also known to involve ROS production in their mechanisms of action. This review gives a brief account of the oxidative stress and redox systems in malaria and discusses the context of antimalarial effectiveness of different ACTs compared with monotherapies of the partner drugs. A final account on the Pros and Cons of ACT as a strategy is discussed.
This item appears in the following Collection(s)
- Academic publications [202801]
- Electronic publications [100942]
- Faculty of Medical Sciences [80020]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.